Product nameAnti-IRF3 (phospho S386) antibody [EPR2346]
See all IRF3 primary antibodies
DescriptionRabbit monoclonal [EPR2346] to IRF3 (phospho S386)
IRF3 (phospho S386) antibody (ab76493) detects IRF3 when phosphorylated on Serine 386.
Tested applicationsSuitable for: WB, Dot blotmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human IRF3 (phospho S386).
Database link: Q14653
- WB: MCF7 cells treated with Calyculin A.
A trial size is available to purchase for this antibody.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.5% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab76493 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 47 kDa.|
FunctionMediates interferon-stimulated response element (ISRE) promoter activation. Functions as a molecular switch for antiviral activity. DsRNA generated during the course of an viral infection leads to IRF3 phosphorylation on the C-terminal serine/threonine cluster. This induces a conformational change, leading to its dimerization, nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of genes under the control of ISRE. The complex binds to the IE and PRDIII regions on the IFN-alpha and IFN-beta promoters respectively. IRF-3 does not have any transcription activation domains.
Tissue specificityExpressed constitutively in a variety of tissues.
Sequence similaritiesBelongs to the IRF family.
Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
modificationsConstitutively phosphorylated on many serines residues. C-terminal serine/threonine cluster is phosphorylated in response of induction by IKBKE and TBK1. Ser-385 and Ser-386 may be specifically phosphorylated in response to induction. An alternate model propose that the five serine/threonine residues between 396 and 405 are phosphorylated in response to a viral infection. Phosphorylation, and subsequent activation of IRF3 is inhibited by vaccinia virus protein E3.
Ubiquitinated; ubiquitination involves RBCK1 leading to proteasomal degradation. Polyubiquitinated; ubiquitination involves TRIM21 leading to proteasomal degradation.
ISGylated by HERC5 resulting in sustained IRF3 activation and in the inhibition of IRF3 ubiquitination by disrupting PIN1 binding. The phosphorylation state of IRF3 does not alter ISGylation.
Cellular localizationCytoplasm. Nucleus. Shuttles between cytoplasmic and nuclear compartments, with export being the prevailing effect. When activated, IRF3 interaction with CREBBP prevents its export to the cytoplasm.
- Information by UniProt
- IIAE7 antibody
- Interferon regulatory factor 3 antibody
- IRF 3 antibody
All lanes : Anti-IRF3 (phospho S386) antibody [EPR2346] (ab76493) at 0.2 µg/ml (purified)
Lane 1 : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates
Lane 2 : MCF7 (Human breast adenocarcinoma epithelial cell) treated with calyculin A for 45 minutes whole cell lysates
Lane 3 : MCF7 (Human breast adenocarcinoma epithelial cell) treated with calyculin A for 45 minutes whole cell lysates. Then the membrane was incubated with phosphatase
Lysates/proteins at 15 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 47 kDa
Blocking and diluting buffer: 5% NFDM/TBST
We are unsure to define the extra band at 37KD.
All lanes : Anti-IRF3 (phospho S386) antibody [EPR2346] (ab76493) at 1/20000 dilution (Unpurified)
Lane 1 : MCF7 cell lysate - treated with Calyculin A
Lane 2 : MCF7 cell lysate – untreated
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
Predicted band size: 47 kDa
Blocking buffer - 5% NFDM/TBST
Diluting buffer - 1% BSA
Dot blot analysis of IRF3 single phospho peptide pS386 (lane 1) and IRF3 non-phospho peptide (lane 2) with unpurified ab76493 at 1/1000. Blocking and diluting buffer was 5% NFDM/TBST. The secondary antibody used was ab97051 Peroxidase conjugated Goat Anti-Rabbit IgG, (H+L) at 1/100,000.
This product has been referenced in:
- Caller LG et al. Temporal Proteomic Analysis of BK Polyomavirus Infection Reveals Virus-Induced G2 Arrest and Highly Effective Evasion of Innate Immune Sensing. J Virol 93:N/A (2019). Read more (PubMed: 31142673) »
- He X et al. RNF34 functions in immunity and selective mitophagy by targeting MAVS for autophagic degradation. EMBO J 38:e100978 (2019). Read more (PubMed: 31304625) »